Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Exclusive relationship through Named Patient Programs establishes footprint in Greece, Cyprus and additional Balkan countriesCR...
Maxim Group analyst Michael Okunewitch upgrades Citius Oncology (NASDAQ:CTOR) from Hold to Buy and announces $6 price target.
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc...
Proprietary model informs targeted sales and marketing strategies with feedback loop thataugments precision and impact of targe...
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.1...
Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a majority-owned subsidiary of Citius...
